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A B S T R A C T
Feline lymphocytic-plasmacytic gingivitis/stomatitis (LPGS) or caudal stomatitis is an inﬂammatory disease
that causes painfully erosive lesions and proliferations of the oral mucosa. The disease is diﬃcult to cure
and can affect cats at an early age, resulting in lifetime therapy. In this study, a new treatment using a
combination of bovine lactoferrin (bLf) oral spray and oral piroxicam was investigated using a random-
ized double-blinded clinical trial in 13 cats with caudal stomatitis. Oral lesion grading and scoring of clin-
ical signs were conducted during and after the trial to assess treatment outcome. Oral mucosal biopsies
were used to evaluate histological changes during and after treatment.
Clinical signs were signiﬁcantly improved in 77% of the cats. In a 4-week study, clinical signs were
considerably ameliorated by oral piroxicam during the ﬁrst 2 weeks. In a 12-week study, the combined
bLf oral spray and piroxicam, when compared with piroxicam alone, exhibited an enhanced effect that
reduced the severity of the oral lesions (P = 0.059), while also signiﬁcantly improving clinical signs (P < 0.05),
quality of life (P < 0.05), and weight gain (P < 0.05). The remission of oral inﬂammation was closely cor-
related with the decreased number of macrophages (OR = 4.719, P < 0.05). There was no detectable in-
ﬂuence on liver or kidney function during a 12-week assessment. It was concluded that combining oral
bLf spray and piroxicam was safe and might be used to decrease the clinical signs of caudal stomatitis
in cats.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Feline lymphocytic-plasmacytic gingivitis/stomatitis (LPGS) or
caudal stomatitis is an intractable oral disease with an incidence
exceeding 3% (Harley, 2003). It is a devastating, chronic inﬂamma-
tory condition that causes painful erosive lesions in the gingival,
buccal regions, and caudal oral mucosa (Sato et al., 1996; Lyon, 2005).
Cats may be affected at an early age and, as the disease is diﬃcult
to cure, it typically requires therapy for life (Dowers et al., 2010;
Hennet et al., 2011). Clinical signs of LPGS include ptyalism, pain,
pawing at the mouth, halitosis, bleeding, weight loss, dysphagia, and
dysorexia. The condition may even require euthanasia because of
poor quality of life (Arzi et al., 2010; Dowers et al., 2010). Abnor-
mal immunological reactions caused by genetic predispositions,
environmental stresses, physiological factors, nutritional factors
(Tenorio et al., 1991; Lyon, 2005), or viral infection (Kobayashi et al.,
2008) have all been correlated with LPGS.
The intractable nature and poor understanding of the
aetiopathogenesis of LPGS have led to widespread use of empiri-
cal or symptomatic treatment regimens in which the clinical re-
sponse has been frequently unsatisfactory (Harley et al., 1999).
Treatments with corticosteroids, antibiotics, interferon, cyclosporine
and chemotherapeutic agents have been reported (Guilford, 1996;
Hennet et al., 2011; Lommer, 2013). Clinicians have frequently used
corticosteroid treatment and surgery to control clinical signs of LPGS,
but these may become less effective with time (White et al., 1992).
Extraction of teeth, including the molars and premolars, has shown
better results, achieving clinical cure in 50–60% of cases (Hennet,
1997; Bellei et al., 2008).
Lactoferrin (Lf) is an 80 kDa glycosylated protein that contains
approximately 700 amino acids, has strong iron-binding aﬃnity, and
has been reported to have multiple functions, including antimicro-
bial, immunomodulatory, anti-inﬂammatory and anti-carcinogenic
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activities (Kobayashi et al., 2008; García-Montoya et al., 2012; Vogel,
2012). Oral administration of Lf can inhibit expression of interfer-
on (INF)-γ and interleukin (IL)-2, and can reduce pain-related re-
sponses, salivation, and anorexia in cats with intractable stomatitis
without signiﬁcant side effects (Sato et al., 1996; Addie et al., 2003;
Kobayashi et al., 2008).
A new treatment combining the non-steroidal anti-inﬂammatory
drug piroxicam and bovine lactoferrin (bLf) was designed to control
the clinical signs of LPGS. This study sought to investigate the po-
tential, as well as possible side-effects, of combined bLf oral spray
and piroxicam for cats with LPGS in a 4-week and a 12-week trial.
Materials and methods
Animals
Twenty-ﬁve cats assumed to have LPGS at local clinics were referred to the Vet-
erinary Medicine Teaching Hospital of National Chung Hsing University (NCHU).
Animals that complied with inclusion and exclusion criteria were enrolled. The in-
clusion criteria consisted of a diagnosis of LPGS conﬁrmed by histopathological ex-
amination of oral mucosa and the presence of clinical signs related to LPGS. Animals
were excluded from the study if they had been administered steroids during themonth
before the study or during the study itself, had concurrent systemic diseases, or had
a history of allergies to anaesthetics or non-steroidal anti-inﬂammatory drugs. This
study was approved by the Institutional Animal Care and Use Committee of NCHU
(IACUC number 100–45; 13 July 2011).
Medical information included sex, breed, bodyweight (BW), history of being a
stray cat and the age at onset of clinical signs. Clinical examination included sub-
mandibular lymph node palpation, complete blood counts, and serological pro-
ﬁles. Full-mouth dental radiography and oral mucosa biopsy were performed
under general anaesthesia. The histopathological features of LPGS are character-
ized by mucosal hyperplasia and inﬁltration, primarily with plasma cells, with
fewer lymphocytes and macrophage-like cells in the oral submucosa. However, the
numbers of neutrophils varies among animals (Harley, 2003; Baird, 2005; Arzi et al.,
2010).
Fourteen of the 25 cats were diagnosed with LPGS, of which 13 were enrolled
after obtaining the informed consent of their owners (the owner of one animal in-
sisted on treatment with steroids only). The other 11 cats were diagnosed as follows:
seven cases of gingivitis, one case of chronic-active gingivitis caused by tartar for-
mation, one case of gingival ulceration, one case of periodontal disease, and one case
of feline tooth resorption lesion.
Study design
The study comprised a randomized double-blinded controlled clinical trial. The
veterinarian and owners were not informed about the grouping at the start of
the study, but the veterinarian was informed following data analysis at the end of
the study. Animals were anaesthetized the day before treatment (D0), and on weeks
2, 4, 8, and 12 (W2, W4, W8, and W12) so as to perform lesion inspections, oro-
pharyngeal swab sampling, and biopsies.
Double-blinded grouping
This study consisted of two stages: (1) from D0 to W4, and (2) fromW5 toW12.
Animals were randomly assigned to the two groups. During the ﬁrst stage, bLf and
piroxicam group was administrated two sprays of bLf oral spray (3 mg/spray, Oral
relax, Happy Harvest Corporation) at 6 mg per cat, twice daily as modiﬁed from pre-
vious studies (Sato et al., 1996; Addie et al., 2003), and piroxicam (Pirocam, Swiss
Pharmaceutical Co.) at 0.3 mg/kg orally on alternate days. The piroxicam group was
given a placebo oral spray (buffer only) in bottles with the same appearance, and
piroxicam in a similar dose. No antibiotics were used. During the second stage, both
groups were administered bLf oral spray and piroxicam. The study asked owners
of both groups to maintain the cats’ usual meals and daily routines.
General anaesthesia and examination of oral mucosal lesions and biopsy
Cats were premedicated with dexmedetomidine (Dexdomitor, Pﬁzer) at a dose
of 250 μg/m2 (intramuscular; IM) or 125 μg/m2 (intravenous; IV) approximately 10min
before general anaesthesia. Propofol (Fresofol, Fresenius Kabi) at 6 mg/kg was ad-
ministered IV for induction. The endpoint for propofol administration was deter-
mined by obtaining suﬃcient jaw relaxation and suppression of pharyngeal reﬂexes.
General anaesthesia was maintained with propofol at 0.3–0.5 mg/kg/min. Oxygen
was delivered during anaesthesia.
Lesions were examined when the cats were under general anaesthesia. The lesion
score (LS) of oral mucosa was assigned a grade of 0–3 according to the criteria shown
in Fig. 1. A biopsy was performed, and this included the areas of normal-like mucosa
Fig. 1. Oral lesion grades and corresponding gross appearances in cats with
lymphocytic-plasmacytic gingivitis/stomatitis (LPGS). The lesion characteristics in
each grade are described in a sequence from mild to severe as following: Grade 0,
inﬂammation is absent without proliferation of the buccal mucosa lateral to pala-
toglossal folds (caudal oral mucosa). No lesion is observed in the tongue or palato-
glossal folds; Grade 1, mild inﬂammation can be seen at the caudal oral mucosa, or
maxillary or mandibular gingiva; protruding proliferative lesions involve only bi-
lateral caudal oral mucosa, but not the palatoglossal folds; Grade 2, moderate in-
ﬂammation involves the bilateral buccal mucosa, gingiva and caudal oral mucosa;
erosive lesions may also be present; nodular proliferations are evident at bilateral
caudal oral mucosa and extend towards the buccal and gingival mucosa of the man-
dible or the tongue, but passage through the fauces is not affected; Grade 3, severe
inﬂammation associated with deep ulcers or ﬁstulas involving the mucosa near the
mandible and caudal oral mucosa; erosive lesions can also be seen at tongue or max-
illary or mandibular gingiva; extensive nodular proliferations affect the caudal oral
mucosa, buccal mucosa, gingiva and even the tongue; passage through the fauces
is obstructed incompletely.
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and inﬂammatory or proliferative tissue. The specimen was ﬁxed in 10% formalde-
hyde for 24 h and then embedded in paraﬃn wax for further histological
examination.
Histological and immunohistochemical (IHC) analyses
Sections (5 μm) were cut and stained with haematoxylin and eosin (H&E) for
histological examination, and with CD3 (dilution of 1:800; A0452, Dako Cytomation)
and CD79a (dilution of 1:200; M7051, Dako Cytomation) antibodies for immuno-
histochemical (IHC) analysis. The IHC was performed according to routine proce-
dures (see Appendix A: Supplementary material in the online version at doi:10.1016/
j.tvjl.2014.06.006) and each batch included a positive control using a feline lymph
node.
The histopathological scoring was assessed by three veterinarians (YPH, YPY and
SCC). The numbers of plasma cells, lymphocytes, neutrophils, macrophages and eo-
sinophils were determined via 10 randomized microscopic high magniﬁcation ﬁelds
(hmfs; 400 × magniﬁcation). The grading systemwas modiﬁed from a previous study
(Arzi et al., 2010). Each cell type was calculated and graded as follows: 0 (nega-
tive), 0.5 (1–10 cells/hmf), 1 (11–50 cells/hmf), 2 (51–100 cells/hmf), and 3 (>101
cells/hmf). Oral mucosa granulation was scored as 0, 0.5, 1, 2, and 3 based on the
numbers of ﬁbroblasts and the amount of collagen and angiogenesis. For section
immunolabelling, three to ﬁve representative hmfs were assessed and the number
of CD3+/CD79a+ cells was calculated.
Evaluation of questionnaires on clinical signs and quality of life
A questionnaire on the clinical signs of LPGS was modiﬁed from a previous
study (Addie et al., 2003) (see Appendix A: Supplementary Table S1 in the online
version at doi:10.1016/j.tvjl.2014.06.006), and included oral pain, ptyalism,
inappetence, inﬂammation of oral mucosa, bleeding, and halitosis. Clinical signs
were graded as follows: 1, absent; 2, mild; 3, moderate, and 4, severe. The owners
were asked to complete the questionnaire weekly. The clinical sign grades were
summed and assigned as the symptom score (SS). Additionally, a quality of life
score (QS) was assigned according to subjective owner observations, and was
scored from 1 to 10, where 1 denoted the worst quality of life, and 10 denoted
the best.
Statistical analysis
The statistical analysis was performed using Statistical Package for the Social
Sciences (v.10.0.7, SPSS). The difference in variables, including LS, SS, QS, and BW,
between the bLf and piroxicam, and piroxicam groups was tested with theWilcoxon
rank sum test. The difference in variables, including LS, SS, QS, and BW, in the same
group compared with D0 was assessed using theWilcoxon signed rank test. The chi-
square test and binary logistic regression were used to establish the correlation
between the cell type or number and the LS or SS. Linear regression analysis was
performed to assess the correlation between the number of macrophages and the
LS. P < 0.05 indicated a statistically signiﬁcant difference between categorized groups.
All values are described as means ± standard error (SE) and median, with a range
from the minimum to maximum values.
Results
Animal characteristics
Of the 13 cats, three (n = 3/13; 23.1%) were excluded because their
owners claimed dissatisfaction with their response to treatment.
Table 1 lists the characteristics of all animals, including the with-
drawn cases. Ten cats completed the 12-week treatment, and all of
these were neutered domestic short-hair cats, including eight males
and two females. These animals had a mean age of 6.93 ± 4.21
(median, 5.5; range, 2–14) years. The average age of onset of clin-
ical signs was 5.47 ± 3.47 (median, 4.5; range, 1.42–12.25) years. The
mean BWwas 4.43 ± 0.95 (median, 4.45; range, 2.93–5.60) kg. Seven
out of 10 animals had a history of being a stray, with an average
time spent roaming of 8.43 ± 3.41 (median, 7.5; range, 2–12) months.
Consequently, ﬁve cats were assigned to the bLf and piroxicam group,
and ﬁve cats to the piroxicam group. The two groups did not differ
signiﬁcantly on D0 (see Appendix A: Supplementary Tables S2 and
S3 in the online version at doi:10.1016/j.tvjl.2014.06.006).
SS, LS, QS, and BW in LPGS cats
Evaluation of the ﬁrst stage from day 0 to week 4
The values of SS, LS, QS, and BW were analyzed and compared
between the two groups and are shown in Fig. 2. The bLf and
piroxicam group showed a continuous reduction of SS, but el-
evated SS was observed in W4 in the piroxicam group. The LS was
decreased in both groups, but the bLf and piroxicam groupwasmore
responsive to treatment. For QS and BW, improvement was ob-
served in the bLf and piroxicam group compared with the piroxicam
group. Positive responses were objectively observed in the bLf and
piroxicam group, although there were no signiﬁcant differences
within or between the two groups.
Evaluation of the ﬁrst and second stage from day 0 to week 12
To assess the longer term effects, changes in SS, LS, QS, and BW
were assessed during the 12-week trial treatment (Fig. 3). From D0
to W2, the SS decreased markedly in both groups. Following W2,
SS in the bLf and piroxicam group gradually reduced, and de-
creased signiﬁcantly in W4 and W8 compared with D0 (P < 0.05).
However, in the piroxicam group, the SS displayed no such reac-
tion, and was elevated in W4 and W12. LS decreased signiﬁcantly
only in the bLf and piroxicam group in W2 compared with D0
(P < 0.05). The QS in the bLf and piroxicam group exhibited a
Table 1
Signalment, medical record and randomized grouping of 13 cats with lymphocytic-plasmacytic gingivitis/stomatitis (LPGS).
Case
number
Randomized group Breed Gender BW
(kg)
Age
(years)
Onset age of
LPGS (years)
Clinical sign
durationa (months)
Lesion
grade
Roaming
time (months)
1b bLf and piroxicam DSH NF 4.6 10 8.8 14 3 12
2 piroxicam DSH NM 5.0 3.6 3.5 1 1 12
3 bLf and piroxicam DSH NM 5.6 4 2.7 17 1 7
4 piroxicam DSH NM 3.9 2 1.5 7 0 9
5 bLf and piroxicam DSH NM 4.6 4 3.4 8 2 8
6b piroxicam DSH NM 4.1 2.6 2.1 5 2 2
7 piroxicam DSH NM 4.3 10 9.5 7 1 0
8b bLf and piroxicam DSH NM 5.0 3 2.1 11 1 10
9 bLf and piroxicam DSH NM 5.0 9 8.1 11 2 0
10 piroxicam DSH NM 4.2 14 12.3 21 1 2
11 bLf and piroxicam DSH NF 3.0 4 3 12 1 12
12 piroxicam DSH NM 5.6 8.6 5.6 36 2 0
13 bLf and piroxicam DSH NF 2.9 7 5.8 16 3 9
BW, bodyweight; bLf, bovine lactoferrin; DSH, domestic short hair; NF, neutered female; NM, neutered male.
a Time between clinical sign identiﬁcation and ﬁnal diagnosis in this study.
b The withdrawn cases because of unsatisﬁed response to treatment from the owners.
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continuous increase, and differed signiﬁcantly in W12 compared
with D0 (P < 0.05). The BW in the bLf and piroxicam group dis-
played a continuous increase, while the piroxicam group showed
a gradual decrease. A signiﬁcant increase (P < 0.05) in BW in
the bLf and piroxicam group was exhibited in W8 compared
with D0.
Accordingly, the bLf and piroxicam group achieved a signiﬁ-
cantly better outcome in terms of amelioration of clinical signs and
oral lesions. Furthermore, the remission of clinical signs in cats with
FLPS improved the appetite and BW. Quality of life also improved
following the 12-week treatment.
Correlation between cell type and lesion/symptom score
The number of plasma cells (OR 4.09, P < 0.05) and CD79a+ cells
(OR 7.49, P < 0.05) was signiﬁcantly increased in the high LS cats
(see Appendix A: Supplementary Fig. S1 in the online version at
doi:10.1016/j.tvjl.2014.06.006). In the high SS cats, only the number
of plasma cells (OR 4.558, P < 0.05) was markedly elevated. The
immunolabelling results of CD79a and CD3 are shown in Appen-
dix A: Supplementary Fig. 2. Binary logistic regression analysis
showed a signiﬁcantly increased the number of macrophages in
the high LS cats (OR 4.719, 95% CI 1.05-21.20, P < 0.05). A positive
correlation between LS and the number of macrophages was ob-
served by the use of linear regression (r < 0.05). Fig. 4 shows that
the number of macrophages increased or decreased with the LS over
the 12-week observation period, except during week 2.
Side effects
Findings of serum chemistry proﬁles revealed no signiﬁcant in-
ﬂuence on hepatic or renal function (see Appendix A: Supplementary
Tables S4 and S5 in the online version at doi:10.1016/j.tvjl
.2014.06.006). Vomiting, diarrhoea or other clinical signs were not
observed during or following the 12-week treatment trial. However,
the oral spray agent was rejected by 20% (n = 2/10) of the animals
(in the piroxicam group) on administration, but bLf could still be
administered by forced administration.
Three withdrawn cats
All three of the cats that were withdrawn from the study showed
anorexia after being administered bLf oral spray or piroxicam for
>1 month. The owners of these animals requested steroid therapy
rather than trial treatment. The animals were withdrawn on W5
(number 8 in the bLf and piroxicam group), W8 (number 6 in the
piroxicam group), and W9 (number 1 in the bLf and piroxicam
group), respectively. The LS was higher (P = 0.076) in these three
cats than in other cats (see Appendix A: Supplementary Table S6
in the online version at doi:10.1016/j.tvjl.2014.06.006).
Fig. 2. The bar charts of the symptom score (SS), lesion score (LS), quality of life score (QS), and bodyweight (BW) in two groups. From D0 to W4, good response to treat-
ment was observed in the bLf and piroxicam group with the SS (from means of 7.2 to 4.4) and LS (from means of 1.6 to 0.8). Similarly, the bLf and piroxicam group out-
performed the piroxicam group in terms of improvement of QS (from means of 5.4 to 6.0) and BW (from means of 4.2 to 4.5). The groups did not differ signiﬁcantly (n = 5
in each group). The error bars indicate the standard error of the mean (SEM).
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Follow-up
After 12weeks of treatment, it was suggested that the piroxicam
treatment be discontinued, while the bLf oral spray was to be con-
tinuously administered. The owners were interviewed by tele-
phone for more than 6months, except for two cats (numbers 2 and
10), for which follow-up information was lost. Of eight cats, 50%
(n = 4/8) maintained their appetite and quality of life; 12.5% (n = 1/
8) needed combined piroxicam and bLf oral spray to maintain ap-
petite, and 12.5% (n = 1/8) were switched to steroid therapy on the
owner’s request. The remaining 25% (n = 2/8) of the cats were able
to maintain most of their appetite and quality of life with bLf oral
spray alone. Though clinical signs in both cats did recur once, they
were followed by rapid remission after an additional 2-week treat-
ment with piroxicam.
Discussion
During the ﬁrst stage, the SS decreased signiﬁcantly during D0
to W2 in both groups, which indicated that piroxicam signiﬁ-
cantly reduced the severity of clinical signs. Additionally, the bLf
and piroxicam group showed improvement in SS, LS, QS, and BW
compared with the piroxicam group from D0 to W4, which sug-
gested that the combined treatment with bLf oral spray and
Fig. 3. The curves of symptom score (SS), lesion score (LS), quality of life score (QS), and bodyweight (BW) over 12 weeks in the bLf and piroxicam and the piroxicam groups
(n = 5 in each group). The SS from D0 to W2 decreased considerably in the bLf and piroxicam group (from means of 7.2 to 5.2), and in the piroxicam group (from means of
7.0 to 4.8). However, from D0 to W12, continuous and steady decreases of SS (from means of 7.2 to 3.4) and LS (from means of 1.6 to 0.8) were only observed in the bLf and
piroxicam group. Continuous improvements also appeared in QS (from 5.4 to 7.2) and BW (from means of 4.2 to 4.5) in the bLf and piroxicam group. Signiﬁcant differences
(P < 0.05) were found in bLf and piroxicam group on W2 (LS), W4 (SS), W8 (BW), and W12 (SS and QS) compared with D0, respectively. *Statistically signiﬁcant difference
compared with D0 in the bLf and piroxicam group.
Fig. 4. Changes in the number of macrophages and lesion score (LS) over 12 weeks.
Except for week 2, the LS correlated with macrophage number during the obser-
vation period (n = 10).
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piroxicam displayed a better outcome than piroxicam alone. In the
12-week study, the clinical signs were well controlled in 77% (n = 10/
13) of cats, and the bLf and piroxicam group exhibited a signiﬁ-
cant improvement in SS, QS, and BW following W8. This indicated
a possible cumulative effect, and thus longer administration of bLf
oral spray might be necessary for an improved response.
Amelioration of oral inﬂammation was closely correlated with
decreased numbers of macrophages in the oral mucosa, which sug-
gests that the combined oral bLf spray and piroxicammight reduce
the number of macrophages, and thus down-regulate cytokine ex-
pression and inhibit inﬂammation. Cytokines such as INF-α, IL-1,
IL-6, IL-12, and IL-18 are released simultaneously by macrophages
to activate T cells and the inﬂammatory response (D’Andrea et al.,
1992; Tizard, 2000). Furthermore, Lf has been reported to be an
immunemodulator and an anti-inﬂammatory agent that acts by in-
hibiting the proliferation of peripheral blood mononuclear cells and
down-regulating cytokines that can stimulate an immune re-
sponse (Kobayashi et al., 2008; García-Montoya et al., 2012; Vogel,
2012). bLf has been reported to be beneﬁcial in oral sanitation
(Masson et al., 1969) because of its strong antimicrobial effects
(Arnold et al., 1977; Ellison et al., 1988; Singh et al., 2002; Berlutti
et al., 2011). Thus, bLf oral spray may inhibit excessive immune re-
sponses or control the recurrence of clinical signs of LPGS through
its antimicrobial effects.
The age of onset of the LPGS cats in this study ranged widely
from 1.5- to 12.3-year-olds, which was similar to previous studies
(Hennet et al., 2011; Robson and Crystal, 2011). Because caudal sto-
matitis can affect animals at an early age, a lifetime of treatment
may be required. Since long-term administrationwith bLf (Sato et al.,
1996; Addie et al., 2003) or piroxicam (Bulman-Fleming et al., 2010)
for periods exceeding 20 months has been well tolerated in cats, a
treatment regimen that combines the two may be suitable for the
long-term administration that is crucial for animals suffering from
LPGS.
Initially, 25 cats were presumed to have LPGS based on their
history, clinical signs and gross lesions. However, following histo-
pathological examination, only 56% (n = 14/25) of the referred cats
were conﬁrmed to have LPGS. Therefore, oral mucosa biopsy is rec-
ommended in cases where it is necessary to conﬁrm LPGS (Lyon,
2005; Harley et al., 2011).
Extracting teeth to reduce plaque-retentive surfaces has proven
to be most effective in eliminating plaque and reducing oral in-
ﬂammation (Hennet, 1997; Lyon, 2005; Bellei et al., 2008) because
the immune system stimulated by plaque bacteria appears to con-
tribute to ongoing inﬂammation (Lommer, 2013). However, recent
studies showed that only approximately 60% of cats with LPGS im-
proved without further medication, 20% needed additional medical
therapy and the other 20% had relapses (Bellei et al., 2008; Hennet
et al., 2011). In our study, two cats (numbers 7 and 8) displayed a
recurrence of LPGS signs following dental extraction of molars and
premolars. Because of the irreversible damage associated with sur-
gical intervention, such operations must be considered only when
animals are non-responsive to medical therapy, and/or suffer from
pain and tooth damage (Lyon, 2005; Bellei et al., 2008).
Conclusions
Positive responses were demonstrated in cats with caudal sto-
matitis using a treatment combining bLf oral spray and oral
piroxicam. Oral administration of the bLf spray reduced macro-
phage numbers, inhibited inﬂammation, and eventually amelio-
rated oral lesions, resulting in improved quality of life. The
combination of the bLf oral spray and orally administered piroxicam
was safe and might be used to decrease clinical signs in cats af-
fected by LPGS with longer administrations recommended to
improve outcomes.
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